COVID-19

Junshi Biosciences Announces Toripalimab as Perioperative Treatment for Operable NSCLC Patients Met Primary Endpoint in Phase 3 Clinical Study

SHANGHAI, China, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a...

AIM ImmunoTech Enters into Pancreatic Cancer Clinical Research Agreements with AstraZeneca and Erasmus Medical Center

Research collaboration will evaluate the potential of AIM’s Ampligen® (rintatolimod) in combination with AstraZeneca’s Imfinzi (durvalumab) for the treatment of...

Blue Water Vaccines Announces Appointment of Seasoned Public Market and Private Equity Investment Leader Timothy Ramdeen to Board of Directors

CINCINNATI, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a...

NewAmsterdam Announces Positive Results from ROSE2, Phase 2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy

-- Achieved primary endpoint with statistically significant reduction in LDL-C (p < 0.0001) ---- Median percent change in LDL-C of...

Omega Therapeutics to Present Trial-in-Progress Poster for Phase 1/2 MYCHELANGELO™ I Study at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium

CAMBRIDGE, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the...

Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) Announces Filing of Definitive Proxy Statement with SEC in Connection with its Proposed Business Combination with Ocean Biomedical, Inc.

NEW YORK and PROVIDENCE, R.I., Jan. 13, 2023 (GLOBE NEWSWIRE) -- Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) (“Aesther”), a special...

error: Content is protected !!